Article Details
Retrieved on: 2021-05-21 17:54:39
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In 2019, biopharmaceutical company RemeGen, needed a new facility for GMP manufacturing of MAbs and ADCs to treat autoimmune diseases. As ...
Article found on: bioprocessintl.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here